Chinese biotech sector will face US threats

Significance The act sought to bar biotech companies “of concern” from federal funding and partnerships with US firms. It specifically named five firms, including BGI Group, WuXi AppTec and WuXi Biologics, citing concerns that they might share genomic data with the Chinese government or military. Impacts Indian, European, South Korean and other firms have an opportunity to win market share in the United States from Chinese biotech companies. US pharmaceutical firms in China, such as Pfizer and Johnson & Johnson, are at risk of retaliation if the bill passes. Chinese biotech firms may expand their investments in the EU and Asian markets to counterbalance US losses.